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ABSTRACT 
Background 
A second antipsychotic is commonly added to clozapine to treat refractory schizophrenia, 
notwithstanding limited evidence to support such practice. 
 
Aims 
To examine the efficacy and adverse effects of this pharmacological strategy. 
 
Method 
Double-blind, placebo-controlled, 12-week RCT of clozapine augmentation with amisulpride, 
involving 68 adults with treatment-resistant schizophrenia and persistent symptoms despite a 
trial of clozapine. 
 
Results 
By 12-week follow-up, amisulpride-treated participants were more likely to fulfil criteria for 
clinical response (OR 1.17 (95% CI 0.40, 3.42)) and had a greater reduction in negative 
symptoms, although neither finding was statistically significant, as well as a higher frequency 
of adverse effects, including cardiac side effects.  
 
Conclusions 
Any modest benefit with the clozapine-amisulpride combination may be delayed beyond the 
4-6 week follow-up considered adequate for acute psychotic episodes. The associated side-
effect burden has implications for the safety and tolerability monitoring of clozapine 
augmentation with a second antipsychotic in clinical and research settings.  
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INTRODUCTION 
In around a third of people with schizophrenia, the illness shows an insufficient response to 
standard treatment with antipsychotic medication. Clozapine is the only antipsychotic 
medication with robust evidence for efficacy in strictly-defined treatment-resistant 
schizophrenia (Warnez & Alessi-Severini 2014). But even then, an adequate response is seen 
in only 30-60% of patients prescribed this drug. (Lieberman et al 1994, Chakos et al 2001). To 
improve efficacy, clinicians commonly augment clozapine with another antipsychotic, although 
the evidence base supporting such a strategy is weak (Barbui et al 2009, Muscatello et al 
2014). The National Institute for Health and Care Excellence guideline for the treatment of 
schizophrenia (NICE 2009) supports clozapine augmentation with a second antipsychotic 
when there has been an inadequate response to clozapine alone, noting than an adequate 
trial of such an augmentation might need to be up to 8–10 weeks, reflecting the findings of our 
own meta-analysis of relevant RCTs (Paton et al 2007). 
 
Clozapine is associated with potentially dangerous side effects such as agranulocytosis, 
myocarditis/cardiomyopathy and seizures as well as relatively common problems of potentially 
serious concern such as weight gain, metabolic side effects and constipation. Thus, the criteria 
for selecting an augmenting antipsychotic drug might reasonably include a low liability to 
compound these side effects. Given its perceived tolerability and safety advantages in relation 
to extrapyramidal side effects (EPS), weight gain and metabolic side effects, amisulpride may 
be considered particularly suitable for clozapine-augmentation therapy (Pani et al 2008). This 
may be one reason why, in the UK, amisulpride is a relatively common choice to augment 
clozapine in clinical practice (Prescribing Observatory for Mental Health 2006, 2007), despite 
the lack of robust clinical evidence on the potential risks and benefits of this drug combination. 
Another reason may be the perception that the selective dopamine D2/D3 blocking properties 
of amisulpride represent a complementary receptor profile to clozapine (Genç et al 2007). 
Clozapine augmentation with a second antipsychotic has generally been found to have only 
modest efficacy although the combination is relatively well tolerated (Sommer et al 2012, 
Taylor et al 2012). The aims of this study were to further test the efficacy of an adequate trial 
of clozapine augmentation with amisulpride compared with placebo in treatment-resistant 
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schizophrenia that had shown an insufficient response to clozapine and to assess the risks 
and possible adverse effects of such a trial.   
 
METHODS 
Design and participants 
The study was a randomised, double-blind, placebo-controlled trial lasting 12 weeks, 
approved by the London-Fulham Research Ethics Committee (Ref: 10/H0711/75), and the trial 
was registered (ISRCTN68824876). Patients were recruited from November 2011 to 
December 2014 from adult mental health services. The main inclusion criteria were treatment 
for at least 12 weeks at a stable dose of 400mg or more of clozapine a day, unless the size of 
the dose was limited by side effects, a total score of 80 or greater at baseline on the Positive 
and Negative Syndrome Scale (PANSS: Kay et al 1987, 1988), a Clinical Global Impression 
scale (CGI: Guy 1976) score of 4 or greater and a Social and Occupational Functioning 
Assessment Scale (SOFAS: Goldman et al 1992) score of 40 or less. In addition, at baseline, 
up to three critical symptoms and/or behaviours that were refractory to treatment were 
identified for each participant. These phenomena had to have been persistent problems and 
judged clinically to have had a major adverse impact on a participant’s social function and 
community re-integration and/or been a major cause of psychological distress, and/or 
precluded discharge from hospital. 
 
Participants were randomised to 400mg amisulpride or one placebo capsule for the first 4 
weeks, with the option of titrating up to 800mg amisulpride or two placebo capsules for the 
remaining eight weeks. The amisulpride and placebo tablets had been encapsulated to look 
identical. A fully automated online (and telephone) randomisation service was provided by the 
Clinical Trials Research Unit, University of Sheffield. In addition, a 24-hour unblinding service 
was provided by ESMS Global, Medical Toxicology Information Service Ltd. 
Changes to methods after trial commencement 
Additional sites were added as the trial progressed, taking the total number of study sites from 
4 to 23. Prior to randomisation of the first participant, electrocardiography was introduced to 
exclude cardiac contraindications and establish a baseline reference for any subsequent 
cardiac monitoring. In line with a number of active, contemporaneous studies that were 
remunerating participants for their time, a payment to participants of £20 for each assessment 
was introduced, in recognition of any expenses incurred (e.g. travel) and inconvenience. 
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Outcomes  
The primary outcome measure was the proportion of patients with a criterion response 
threshold of a 20% reduction in total PANSS scale score. The inter-rater reliability of the 
PANSS ratings by researchers across the study sites was formally tested: the intra-class 
correlation for individual items was 0.63 (moderate agreement) and subscales at 0.86 
(substantial agreement). The PANSS and the other ratings scale were administered at 
baseline, six weeks and twelve weeks. 
 
Negative symptoms were assessed using the PANSS negative symptom subscale score. The 
impact on social and occupational function was measured using the SOFAS. The level of 
engagement with clinical services was assessed using the Service Engagement Scale (SES: 
Tait et al 2002).  Depressive symptoms were assessed using the Calgary Depression Rating 
Scale for Schizophrenia (CDSS: Addington et al 1993). Insight was assessed using the 
Schedule for the Assessment of Insight (SAI: David 1990). The Antipsychotic Non-
Neurological Side Effects Scale (ANNSERS: Ohlsen et al 2008), systematically and 
comprehensively assessed the full range of side effect, other than movement disorders, that 
are recognised as occurring with first and/or second generation antipsychotics. For this study, 
an enhanced version of the scale was generated (ANNSERS-E) by the addition of potential 
cardiac symptoms such as palpitations, dizziness and syncope. Metabolic side effects were 
assessed at baseline, and 12-week follow-up only, using an obesity measure and assessment 
of blood pressure, serum prolactin, plasma glucose (non-fasting sample) and lipid profile. In 
line with best practice safety monitoring (Royal College of Psychiatrists 2006), an ECG was 
carried out and reported on at baseline, before the study medication was initiated. This was in 
order to establish a baseline for any subsequent cardiac monitoring, and exclude cardiac 
contraindications to potentially high-dose antipsychotic medication, including long QT 
syndromes. 
 
With regard to EPS, drug-induced Parkinsonism was assessed using the Simpson and Angus 
(1970) Extrapyramidal Side Effects Scale (EPSE: Janno et al 2005). The Barnes Akathisia 
Rating Scale (BARS: Barnes 1989) was used to assess akathisia and the Abnormal 
Involuntary Movement Scale (AIMS: Guy 1976, National Institute for Mental Health in England 
2008) for rating tardive dyskinesia. The study researchers received thorough training on the 
use of these measures. 
 
Statistical analysis  
Our sample size calculation was based on results from previous studies (Josiassen et al 2005, 
Shiloh et al 1997), which were comparable with the current study in terms of length of follow-
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up, the nature of the intervention and the primary outcome, a 20% or greater reduction in total 
PANSS score. To detect this criterion response in 30% of participants in the amisulpride arm 
and 10% in the placebo arm, with 90% power and an alpha of 0.05, would require 92 
participants per group (two-sided).  
 
All the main analyses were based on Intention-to-Treat. Baseline summary statistics by 
randomised group were calculated. Group differences in the primary outcome and other binary 
outcome measures were evaluated through the use of logistic regression after allowing for 
stratification by baseline symptom severity. Differences in continuous outcome measures 
were evaluated through corresponding analysis of covariance (ANCOVA) model, controlling 
for baseline symptom severity (the stratification variable), and baseline values of the outcome 
in question.  
The six-week data were used to determine whether there was benefit from the intervention 
earlier than the twelve-week follow-up. The six-week outcome data were examined as a 
(tertiary) outcome, looking at the data longitudinally using mixed effects modelling using both 
six and twelve-week outcomes and controlling for baseline values of the given measure. Data 
were analysed using Stata version 13 for Windows (StataCorp. 2013). 
RESULTS 
Of the 96 patients recruited, 68 were randomised, with 52 completing their assigned treatment 
regimen and assessment at the 12-week follow-up. Figure 1 is the CONSORT diagram of 
progress through the phases of the trial. Table 1 shows the demographic characteristics and 
status of the participants in the two treatment groups at baseline while Table 2 provides 
information on the clinical characteristics. Of the critical symptoms and/or behaviours 
refractory to treatment identified at baseline by the responsible clinical team, positive 
symptoms were most the most common: hallucinations were reported for 51% of participants, 
delusions for 43%, and suspiciousness/persecutory or paranoid ideas for 33%. Reduced 
social interaction was identified as a problem for 37%. Anxiety was relatively common, being 
identified as a persistent issue for 35% of participants, while depression was a key symptom 
in only 9%. General negative symptoms were mentioned for 12% of participants but, more 
specifically, 20% of participants were reported as having lack of drive, motivation, volition 
and/or spontaneity.  
 
At the 6-week study assessment, the mean PANSS total score was higher for the placebo 
group (85 [SD 23]) compared with the amisulpride group (80 [SD 15]), although the same 
proportion (25%) had a 20% drop in PANSS score from baseline in both groups.  Median SES 
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was lower in the placebo group (7 [IQR 4, 14]) compared with the amisulpride group (10 [IQR 
4, 13]).  All other standardised scales showed similar scores between groups. 
Table 1. Demographic characteristics and status of participants at baseline, by 
randomised groups 
 
Variable 
Amisulpride Placebo 
n/N or mean % or (SD) n/N or mean % or (SD) 
Male 24/35 69 23/33 70 
Age: years 39 (11) 40 (10) 
Ethnicity: White 28/35 80 24/33 73 
     
Living alone 12/32 38 11/28 39 
Living with parents 5/32 16 8/28 29 
Living with others 15/32 47 9/28 32 
     
Owner occupied flat or house 0/34 0 0/29 0 
Flat or house rented 19/34 56 21/29 72 
Other accommodation 15/34 44 8/29 28 
     
Not in paid employment because 
of treatment 
24/25 96 23/25 92 
     
Currently an inpatient 5/35 14 4/33 12 
Psychiatric inpatient in the last 3 
months 
1/22 5 0/20 0 
 
Figure 1. The CONSORT flow diagram. IMP, investigational medicinal product. 
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Table 2. Clinical characteristics of participants at baseline, by randomised groups 
Variable Amisulpride Placebo 
 n/N or mean % or (SD) n/N or mean % or (SD) 
Primary psychiatric diagnosis     
Schizophrenia 32/34 94 29/30 97 
Schizophreniform disorder 1/34 3 0/30 0 
Schizoaffective disorder 1/34 3 0/30 0 
Psychosis NOS 0/34 0 1/30 3 
 
Medication 
    
Any antidepressant 15/35 43 13/33 39 
Any antipsychotic (excluding clozapine 
and amisulpride) 
3/35 9 1/33 3 
Any mood stabiliser 9/35 26 4/33 12 
 
Cardiac symptoms, checked 7-10 days 
after starting study medication 
    
Irregular heartbeat 1/31 3 0/26 0 
Shortness of breath 5/32 16 0/26 0 
Dizziness 5/32 16 1/26 4 
Fainting 0/31 0 0/26 0 
Hypotension 0/30 0 0/26 0 
 
Clinical assessment 
    
Mental state: PANSS 93 (13) 98 (24) 
PANSS high score (stratification 
variable) 
16/35 46 14/33 42 
PANSS negative symptom subscale 
score 
25 (6) 25 (7) 
Depression: CDSS median (IQR) 5 (1, 10) 5 (2, 8) 
Social function: SOFAS median (IQR) 35 (32, 39) 35 (30, 40) 
Service engagement: SES median (IQR) 8 (4, 13) 10 (4, 18) 
Insight: SAI median (IQR) 12 (8, 13) 12 (9, 14) 
 
Side-effects 
    
ANNSERS-E median (IQR) 16 (11, 22) 13 (10, 24) 
BARS: median (IQR) 0 (0, 2) 2 (0, 2) 
      Akathisia present (score 2+) 3/33 9 4/31 13 
AIMS positive: tardive dyskinesia 4/35 11 4/33 12 
EPSE: median (IQR) 0.1 (0, 0.3) 0.1 (0, 0.3) 
      Parkinsonism present 10/29 34 6/24 25 
 
A 20% or greater reduction in PANSS total score by 12 weeks was found in 44% of those 
participants in the amisulpride group compared with 40% of those assigned to placebo. As 
can be seen from the data presented in Table 3, this reflects higher odds (OR 1.17 [95% CI 
0.40, 3.42]) for the amisulpride group for achieving this criterion level of reduction in PANSS 
total score.  Table 4 presents the results of mixed effects modelling to take time into account 
in terms of the amisulpride intervention. These reveal a time effect associated with >20% 
reduction in PANSS; the odds of a >20% reduction in PANSS at 12 weeks is 4.19 times that 
of 6 weeks (95% CI 1.20, 14.56), controlling for baseline PANSS score and including the 
randomised condition.  Likewise, PANSS negative subscale scores show a slight decrease 
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in score at 12 weeks compared with 6 weeks (-1.32; 95% CI -2.20, -0.44) controlling for 
baseline negative PANSS score and including the randomised condition.  
 
Table 3: Outcomes in terms of the amisulpride intervention 
Variable OR or 
coefficient 
95% CI 
Primary outcome   
>20% reduction in PANSS from baseline 1.17 (0.40, 3.42) 
   
Secondary outcomes   
PANSS negative symptom subscale -0.71 (-3.22, 1.81) 
   
Service engagement: SES 1.17 (-1.63, 3.97) 
Depression: CDSS 0.23 (-1.54, 2.00) 
Insight: SAI 0.02 (-1.33, 1.37) 
   
Side effects   
Non neurological   
ANNSERS-E 1.58 (-3.60, 6.76) 
   
Metabolic/endocrine side effects   
Weight 0.79 (-1.40, 2.99) 
Body mass index -0.02 (-1.05, 1.01) 
Waist circumference 1.05 (-2.33, 4.42) 
Systolic blood pressure (mmHg) 3.49 (-3.66, 10.63) 
Diastolic blood pressure (mmHg) 3.33 (-1.65, 8.31) 
   
Serum prolactin (ng/ml) 50.47 (-8.86, 109.80) 
Ln serum prolactin 1.43 (0.71, 2.14) 
   
Plasma glucose (mmol/l): non-fasting blood 
sample 
0.66 (-0.22, 1.54) 
Total cholesterol (mmol/l) 0.48 (-0.11, 1.07) 
HDL cholesterol (mmol/l) 0.09 (-0.23, 0.41) 
LDL cholesterol (mmol/l) 0.11 (-0.62, 0.85) 
Triglycerides (mmol/l) 0.78 (-0.10, 1.65) 
   
Motor side effects   
Akathisia: BARS global item score ≥2 * 0.35 (0.06, 2.09) 
Tardive dyskinesia: AIMS positive* 0.37 (0.03, 4.34) 
Parkinsonism: EPSE -0.04 (-0.22, 0.14) 
Extrapyramidal side-effects present* 0.63 (0.18, 2.20) 
*unadjusted result, too few events to do an adjusted analysis 
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Table 4: Mixed effects modelling to take time into account in terms of the amisulpride 
intervention 
 
Variable OR or 
coefficient 
95% CI 
Primary outcome   
20% reduction in PANSS from baseline 1.43 (0.24, 8.44) 
   
Secondary outcomes   
PANSS negative symptom subscale -0.60 (-2.58, 1.39) 
Service engagement: SES 1.75 (-0.54, 4.04) 
Depression: CDSS 0.19 (-1.10, 1.49) 
Insight: SAI -0.52 (-2.32, 1.28) 
   
Side effects   
ANNSERS-E 3.11 (-0.91, 7.13) 
Akathisia present: BARS global item score 
≥2 
0.29 (0.01, 7.82) 
Tardive dyskinesia: AIMS positive  0.18 (0.00, 32.67) 
Parkinsonism: EPSE 0.05 (-0.09, 0.19) 
 
 
 
Side effects 
The information in Table 2 shows a greater frequency of cardiac symptoms in the amisulpride 
group, when checked 7-10 days after starting study medication. The data in Table 4 regarding 
side-effect assessment using the ANNSERS-E, reveal that, over the course of the study, the 
mean ANNSERS-E total score in those participants assigned to amisulpride was 3 points 
higher than in the placebo group.  
 
By 12 weeks, mean weight, BMI, waist circumference and blood pressure were greater in the 
amisulpride group than in the placebo group. Median plasma prolactin concentration was 
higher in the amisulpride group than in the placebo group [43 ng/ml (IQR 9–87 ng/ml) vs. 11 
ng/ml (IQR 7–12 ng/ml), respectively], as was mean plasma glucose concentration [6.9 mmol/l 
(SD 2.8 mmol/l) vs. 5.4 mmol/l (SD 0.7 mmol/l), respectively].  
During the course of the study, 65 adverse events were reported for 31 participants; more of 
these events were in the amisulpride intervention group than the placebo group (47 versus 
18). Most of the adverse events reported were characterised as mild and eventually resolved. 
Almost a third of adverse events in the amisulpride group were judged by the reporting clinician 
to be either ‘probably’ or ‘definitely’ related to the study medication compared with a little over 
a tenth in the placebo group. In the amisulpride group, 60% had at least one adverse event 
compared with 30% in the control group. 40% of adverse events in the amisulpride group were 
cardiac symptoms (compared with 11% of the adverse events in the placebo group): dizziness 
and breathlessness were the most common, each reported by 6 participants, with postural 
dizziness, irregular heartbeat and tachycardia each reported by 2 participants. However, 
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serious adverse events were rare and none related to the study medication, with one 
participant experiencing such an event in the amisulpride group and two participants in the 
placebo group.   
 
DISCUSSION  
Efficacy 
The only other double-blind, placebo-controlled study testing amisulpride augmentation of 
clozapine in patients with schizophrenia that has shown an insufficient response to clozapine 
treatment was by Assion et al (2008). These investigators concluded that this was a potentially 
helpful treatment option in such cases but acknowledged the limitations of their small sample 
size and relatively short, 6-week follow-up. Our trial had a much larger sample size and longer 
follow-up but we under-recruited against our target sample size and therefore the power of 
any statistical analysis to detect significant differences between the active and placebo groups 
was limited. Nevertheless, we found that the participants in the amisulpride group had higher 
odds of being clinical responders by the end of the 12-week study period, the response 
criterion being a 20% or greater reduction in the total PANSS score. This advantage was not 
evident at 6 weeks, reinforcing earlier indications that an adequate trial of clozapine 
augmentation with a second antipsychotic may be at least 10 to 12 weeks (Paton et al 2007, 
Correll et al 2009), that is, longer than the 4-6 weeks usually considered adequate for the 
treatment of an acute psychotic episode.  
 
There was some evidence of a greater reduction in the PANSS negative symptom subscale 
score by 12 weeks in those participants assigned to amisulpride, compared with the placebo 
group. This finding is in accord with earlier reports of a greater improvement in negative 
symptoms than positive symptoms in randomised studies where clozapine augmentation with 
a second antipsychotic for treatment-refractory schizophrenia has proved to be beneficial 
(Chang et al 2008, Josiassen et al 2005) as well as some limited evidence for improvement in 
negative symptoms with amisulpride monotherapy (Boyer et al 1995, Loo et al 1997, Danion 
et al 1999, Storosum et al 2002, Arango et al 2013). 
 
When considering these findings it should be borne in mind that a response criterion of a 20% 
or greater reduction in total PANSS score for people with treatment-refractory schizophrenia 
may be of limited clinical relevance. Its interpretation requires an understanding of the 
meaning of scores on a scale rarely used in clinical practice. Further, as Leucht et al (2006) 
demonstrated, even a 25% reduction in the PANSS total score may only reflect a reduction of 
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the Clinical Global Impression scale score by one severity step. Given the marked 
heterogeneity of the clinical presentation of treatment-refractory schizophrenia, a more 
clinically relevant outcome measure in future studies of this kind might be an individualised 
response criterion, based on the change in severity of each participant’s critical target 
symptoms. This last point is reinforced by the diverse clinical profiles presenting in this study 
sample. While persistent positive symptoms were the most common features at baseline 
judged to be of clinical significance by the mental health professionals providing care, some 
participants presented other such target symptoms and behaviours, including anxiety, reduced 
social interaction, and negative symptoms in the avolition/amotivation domain.  
Side effects 
Amisulpride was chosen for this study because of the robust evidence for safety and 
tolerability benefits, particularly a low risk of compounding characteristic clozapine side effects. 
Amisulpride may be rather more likely than most other second-generation antipsychotics to 
cause hyperprolactinaemia (Fric & Laux 2003) but it causes little or no weight gain and has a 
relatively low liability for diabetes, lipid abnormalities and EPS (Tschoner et al 2007, Leucht et 
al 2013). With regard to cardiac side effects, QT interval prolongation and the potentially fatal 
arrhythmia, torsade de pointes, are not uncommon with overdose (Isbister et al 2010) but the 
risk at therapeutic dosages is rather uncertain (McKeage & Plosker 2004, Chung & Chua 
2010). 
Using the ANNSERS-E scale, we found a greater side-effect burden in those participants 
assigned to the clozapine-amisulpride combination. Their mean ANNSERS-E total over the 
course of the study was 3 points higher than the equivalent score in the placebo group. 
However, our separate scale assessments of EPS, such as akathisia and parkinsonism, 
revealed that these were not likely to be treatment-emergent problems with amisulpride 
augmentation of clozapine, despite the ‘high rates’ of tremor, bradykinesia and akathisia 
previously reported with the combination (Assion et al 2008, Porcelli et al 2012). 
Considering the adverse events reported during the course of the study, 60% of participants 
in the amisulpride group had at least one reported, compared with 30% of participants in the 
placebo group. Cardiac symptoms proved to be a relatively common prompt for an adverse 
event report, occurring much more commonly in the amisulpride group. Further, an additional 
check for any emerging cardiac symptoms in the 7 to 10 days after starting study medication 
revealed that shortness of breath and dizziness were more common in the amisulpride group. 
Amisulpride augmentation was also associated with endocrine effects; the most common was 
raised plasma prolactin, an expected side effect that also provides some indirect but 
reassuring evidence of adherence to the study medication.   
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Mechanism of action 
One proposed criterion for the choice of an augmenting antipsychotic in patients on clozapine 
is a complementary receptor profile, essentially potent D2 dopamine receptor blockade 
(Freudenreich & Goff 2002, Genç et al 2007, Kontaxakis et al 2006). This was partly the 
rationale for choosing amisulpride for this study: it preferentially binds to dopamine D2 and D3 
receptors in limbic rather than striatal brain structures (Moller et al 2003, Perrault et al 1997) 
and has low affinity for other dopamine receptor subtypes, although it also has affinity for a 
range of other receptors, including serotonergic, histaminergic and adrenergic receptors.  
 
However, the limited benefit seen with amisulpride in this study suggests that the notion that 
potent D2 blockade is a key determinant of response when adding a second antipsychotic to 
treat clozapine-unresponsive illness may be simplistic. Treatment-refractory schizophrenia 
may have a more complex pathophysiology than illness showing a good therapeutic response 
to standard antipsychotic therapy; the underlying pathophysiology may even be non-
dopaminergic (Howes & Kapur 2014, Nakajima et al 2015, Mouchlianitis et al 2016). For 
example, dopamine synthesis capacity is lower in those patients with a treatment-resistant 
illness (indeed, no different from healthy controls) than in those with a responsive illness 
(Demjaha et al 2012). It has been speculated that treatment-resistant illness may benefit from 
a multi-site receptor effect rather than a stronger antidopaminergic effect (Vayisoğlu & 
Yağcioğlu 2014, Muscatello et al 2014).  
 
Conclusions 
We found that even amongst patients with a clozapine-refractory illness, there was a greater 
chance of improvement to a criterion level of overall symptom reduction within 12 weeks and 
some suggestion of modest improvement in negative symptoms. However, despite 
amisulpride being chosen for its favourable tolerability and safety profile, when combined with 
clozapine treatment in this study it was associated with a greater side-effect burden, including 
cardiac side effects. The identification of such problems may partly reflect the thorough 
assessment of side effects in this study, which was more systematic and comprehensive than 
is generally conducted in clinical trials of antipsychotics (Pope et al 2010). These findings have 
implications for the nature and frequency of safety and tolerability monitoring of clozapine 
augmentation with a second antipsychotic in both clinical and research settings.  
 
The limited benefit with amisulpride seen in this trial challenges the rationale of potent 
dopamine D2 receptor blockade as a key criterion for selecting an augmenting antipsychotic 
to treat clozapine-unresponsive illness. Nevertheless, the findings suggest that the risk-benefit 
of amisulpride augmentation of clozapine for schizophrenia that has shown an insufficient 
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response to a trial of clozapine monotherapy may still be worthy of further investigation in 
larger studies.  
Future trials of such a treatment strategy should have a sample size that provides adequate 
statistical power and be of sufficient duration, taking into account that a clinical response may 
not be evident within the 4-6 week follow-up period usually considered adequate in studies of 
antipsychotic treatment of acute psychotic episodes. Whether such trials are feasible remains 
uncertain, given the continuing challenge of recruitment in mental health studies in the NHS 
(Rendell et al 2007, Leeson & Tyrer 2013, Barnes et al 2016). 
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